fred saad, esmo 2022: phase iii propel trial of abiraterone olaparib in prostate cancer
Published 1 year ago • 413 plays • Length 4:56Download video MP4
Download video MP3
Similar videos
-
3:41
olaparib plus abiraterone could be a new first-line treatment option for mcrpc | fred saad
-
5:36
propel trial
-
1:19
highlights in prostate cancer from esmo
-
28:31
prostate cancer highlights from esmo 2022
-
13:40
2022 recap: new treatments and approaches in #prostatecancer | #markscholzmd | pcri
-
6:29
prostate cancer: what men need to know
-
16:11
peace-1 trial results with dr. alberto bossi
-
0:52
clinical trial updates in prostate cancer at esmo 2022
-
3:07
propel: olaparib plus abiraterone as 1l treatment for metastatic crpc
-
1:00
esmo 2022 highlights
-
4:08
propel: final os of first-line abiraterone plus olaparib for mcrpc
-
8:51
esmo 2020 expert video report on precision medicine in prostate cancer
-
2:45
biomarker analysis and updated results from propel
-
2:45
#esmo21 highlights on mfs analysis from comb. treatments in high-risk adv. prostate cancer: stampede
-
2:21
#esmo22 highlights on adt duration with post-operative radiotherapy in prostate cancer: radicals-hd
-
4:02
precision medicine in prostate cancer
-
3:47
elucidating hrrm status in patients with mcrpc in the propel trial
-
35:26
esou online: eau22 highlights in prostate cancer
-
10:51
advanced prostate cancer clinical trials update 2022
-
2:18
#esmo21 highlights on maintenance olaparib in ovarian cancer previously treated with parpi
-
4:33
#esmo21 expert video report on prostate cancer
-
7:29
myriam chalabi, esmo 2022: neoadjuvant immune checkpoint inhibition in mmr-deficient colon cancer